Case Report
BibTex RIS Cite

Year 2019, Volume: 9 Issue: 1, 91 - 93, 29.03.2019

Selami Aykut Temiz Arzu Ataseven İlkay Ozer Recep Dursun Siddika Findik

https://doi.org/10.33808/marusbed.546841
Cited By: 1

Abstract

References

  • [1] Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6(4):1162-70.
  • [2] Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology (Oxford) 2018; 57(8):1400- 07.
  • [3] Kavala M, Türkoğlu Z, Özlü E. Metotreksat ve dermatolojide klinik kullanımları. Med Med J 2014; 29:104-110.
  • [4] Sunderkötter C, De Groot K. Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 2008; 59:382.
  • [5] Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311-40.
  • [6] Polat AK, Belli AA, Karakus V, Dere Y. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol 2017; 92:59-61.
  • [7] Black AK. Urticarial vasculitis. Clinics in Dermatology 1999; 17:565-69.
  • [8] Katsambas A, Riga P. Purpura and vasculitis: unapproved treatments. Clin Dermatol 2002; 20:626-33.
  • [9] Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009; 123:1226-36.
  • [10] 1Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18.
  • [11] Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10:1279-89.
  • [12] Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36-38.
  • [13] Perez A, Woods A, Grattan CEH. Methotrexate: a useful steroidsparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191-94.
  • [14] Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
  • [15] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology 2014; 10:1519-30.

Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?

Year 2019, Volume: 9 Issue: 1, 91 - 93, 29.03.2019

Selami Aykut Temiz Arzu Ataseven İlkay Ozer Recep Dursun Siddika Findik

https://doi.org/10.33808/marusbed.546841
Cited By: 1

Abstract

Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically
characterized by leukocytoclastic vasculitis. The pathogenesis is thought to be developed by a type III hypersensitivity reaction similar to
leukocytoclastic vasculitis.
Methods: Antihistamines and/or corticosteroids (systemic/local) may be used in patients with limited normocomplementemic urticarial vasculitis.
In the literature, severe cases treated with dapsone, colchicine, hydroxychloroquine, pentoxifylline, omalizumab, mycophenolate mofetil, rituximab,
cyclosporine, intravenous immunoglobulin, and cyclophosphamide have been reported in the case reports.
Results: In this case, the patient, whose symptoms had not previously responded to treatment with antihistamines, steroids, cyclosporine, and
omalizumab, responded to treatment with methotrexate.
Conclusion: This case report recommends that methotrexate therapy may be a treatment option for cases of resistant urticarial vasculitis.

Keywords

Urticarial vasculitis methotrexate omalizumab

References

  • [1] Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6(4):1162-70.
  • [2] Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology (Oxford) 2018; 57(8):1400- 07.
  • [3] Kavala M, Türkoğlu Z, Özlü E. Metotreksat ve dermatolojide klinik kullanımları. Med Med J 2014; 29:104-110.
  • [4] Sunderkötter C, De Groot K. Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 2008; 59:382.
  • [5] Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311-40.
  • [6] Polat AK, Belli AA, Karakus V, Dere Y. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol 2017; 92:59-61.
  • [7] Black AK. Urticarial vasculitis. Clinics in Dermatology 1999; 17:565-69.
  • [8] Katsambas A, Riga P. Purpura and vasculitis: unapproved treatments. Clin Dermatol 2002; 20:626-33.
  • [9] Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009; 123:1226-36.
  • [10] 1Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18.
  • [11] Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10:1279-89.
  • [12] Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36-38.
  • [13] Perez A, Woods A, Grattan CEH. Methotrexate: a useful steroidsparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191-94.
  • [14] Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
  • [15] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology 2014; 10:1519-30.
There are 15 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Report
Authors

Selami Aykut Temiz 0000-0003-4878-0045

Arzu Ataseven This is me 0000-0001-5372-0712

İlkay Ozer This is me 0000-0001-6170-0930

Recep Dursun This is me 0000-0002-1279-574X

Siddika Findik This is me 0000-0002-3364-7498

Publication Date March 29, 2019
Submission Date April 16, 2018
Published in Issue Year 2019 Volume: 9 Issue: 1

Cite

APA Temiz, S. A., Ataseven, A., Ozer, İ., Dursun, R., et al. (2019). Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences, 9(1), 91-93. https://doi.org/10.33808/marusbed.546841
AMA Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S. Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences. March 2019;9(1):91-93. doi:10.33808/marusbed.546841
Chicago Temiz, Selami Aykut, Arzu Ataseven, İlkay Ozer, Recep Dursun, and Siddika Findik. “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”. Clinical and Experimental Health Sciences 9, no. 1 (March 2019): 91-93. https://doi.org/10.33808/marusbed.546841.
EndNote Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S (March 1, 2019) Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences 9 1 91–93.
IEEE S. A. Temiz, A. Ataseven, İ. Ozer, R. Dursun, and S. Findik, “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”, Clinical and Experimental Health Sciences, vol. 9, no. 1, pp. 91–93, 2019, doi: 10.33808/marusbed.546841.
ISNAD Temiz, Selami Aykut et al. “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”. Clinical and Experimental Health Sciences 9/1 (March 2019), 91-93. https://doi.org/10.33808/marusbed.546841.
JAMA Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S. Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences. 2019;9:91–93.
MLA Temiz, Selami Aykut et al. “Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?”. Clinical and Experimental Health Sciences, vol. 9, no. 1, 2019, pp. 91-93, doi:10.33808/marusbed.546841.
Vancouver Temiz SA, Ataseven A, Ozer İ, Dursun R, Findik S. Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences. 2019;9(1):91-3.

Cited By

Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria
Clinical Case Reports
https://doi.org/10.1002/ccr3.5930
 Download Cover Image

14639   14640